Corbus Pharmaceuticals Stock (NASDAQ:CRBP)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$13.00

52W Range

$5.30 - $61.90

50D Avg

$16.87

200D Avg

$37.65

Market Cap

$160.28M

Avg Vol (3M)

$457.40K

Beta

2.56

Div Yield

-

CRBP Company Profile


Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

19

IPO Date

Oct 27, 2014

Website

CRBP Performance


CRBP Financial Summary


Dec 23Dec 22Dec 21
Revenue--$881.71K
Operating Income$-44.60B$-39.84M$-55.99M
Net Income$-44.60B$-55.83M$-45.55M
EBITDA$-44.60B$-29.50M$-56.27M
Basic EPS$-10.31$-13.39$-11.11
Diluted EPS$-10.31$-13.39$-11.11

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 20Mar 15, 21 | 12:24 PM
Q3 20Nov 10, 20 | 12:00 AM
Q2 20Aug 06, 20 | 5:00 PM

Peer Comparison


TickerCompany
CUECue Biopharma, Inc.
ZVSAZyVersa Therapeutics, Inc.
BCABBioAtla, Inc.
DAWNDay One Biopharmaceuticals, Inc.
SPROSpero Therapeutics, Inc.
GLMDGalmed Pharmaceuticals Ltd.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
ANTXAN2 Therapeutics, Inc.
NXTCNextCure, Inc.
CTMXCytomX Therapeutics, Inc.
KODKodiak Sciences Inc.
AFMDAffimed N.V.
ASMBAssembly Biosciences, Inc.
ADVMAdverum Biotechnologies, Inc.
ABOSAcumen Pharmaceuticals, Inc.
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.
OCEAOcean Biomedical, Inc.
TRVITrevi Therapeutics, Inc.